ECCMID

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Tuesday, April 9, 2024
Antimalarial medication, Polyene, Fungal infection, Candidiasis, Congress, Biotechnology, Azole, Candida auris, Patient, Mouse, Infection, University, NOS, Echinocandin, University of Texas System, Fluconazole, ECCMID, European, Candida glabrata, Pharmaceutical industry

These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.

Key Points: 
  • These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.
  • Candida auris is an emerging fungal pathogen associated with nosocomial infections and considered a serious global health threat.
  • The work here utilized the National Institute of Allergy and Infectious Diseases’ (NIAID’s) suite of preclinical services for in vivo testing (Contract Nos.
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
Research, Hepatitis, CAM, Stop, KU Leuven, AASLD, Annual general meeting, SAN, EASL, MASH, MBA, Hepatology, Investment, Clinical trial, Therapy, Phase II, Interim, ECCMID, Infection, CHB, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2023.
  • R&D expenses for the year ended December 31, 2023, were $73.0 million, compared with $85.1 million for the same period of 2022.
  • G&A expenses for the year ended December 31, 2023, were $30.6 million, compared with $26.4 million for the same period of 2022.
  • Total G&A stock-based compensation expense incurred for the year ended December 31, 2023 was $5.8 million, compared with $6.7 million for the same period of 2022.

A.C. Camargo Cancer Center Harnesses the Power of DoseMe Precision Dosing Platform to Substantially Reduce Toxicity and Kidney Injuries

Retrieved on: 
Wednesday, August 30, 2023
Managed Care, Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Hospitals, Health Technology, Clinical Trials, Science, Health, BCPS, PM, Doctor of Pharmacy, University, Education, Evidence-based medicine, Post, Serum, Acute kidney injury, Survival, Infection, Cancer, International Association, Rehabilitation, Clinical endpoint, Doctor of Philosophy, ECCMID, Vancomycin, Patient, Collection, Nursing, Therapeutic drug monitoring, Diagnosis, Hospital, Yale Cancer Center, TDM, Pharmaceutical industry, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.
  • A.C. Camargo is an integrated Cancer Center for diagnosis, treatment, education and research.
  • Since its inception in 1953, A.C. Camargo has made significant and ongoing contributions to the fight against cancer and it is recognized internationally as a reference institution.
  • "DoseMe is critical to our team's ability to access real-time data and continue to deliver on our promise of customized care for every single patient."

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Workforce, Mucorales, GSK, Hansoh Pharmaceutical, IV, SG, Ibrexafungerp, General Administration of Sport of China, Biotechnology, NDA, NIH, Candidiasis, Global health, Tablet, End-user license agreement, Silicon, Congress, Antimalarial medication, ECCMID, VVC, Investment, European, License, Research, IND, NMPA, Infection, Auris, FURI, Pharmaceutical industry, Cryptocurrency

JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.
  • On June 21, 2023, SCYNEXIS announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.
  • Selling, general & administrative (SG&A) expense for Q2 2023 decreased to $7.5 million from $15.8 million for Q2 2022.
  • Total other income was $5.7 million for Q2 2023, versus total other income of $8.4 million for Q2 2022.

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, August 9, 2023
KRAS, Chemistry, Congress, Lance, Patient, SLATE, Collaboration, Infection, Maintenance, Monitoring, Vaccination, Gritstone bio, Immunity, Research, Melinda French Gates, Gilead, ECCMID, CORAL, NCI, Vaccine, DNA, AACR, COVID-19, African, Cancer, NAB, Immunotherapy, Messenger, Government, Friends, National Cancer Institute, Bill & Melinda Gates Foundation, European, NIAID, Partnership, Circulating tumor DNA, Drug development, CRC, HIV, CMC, Clinical trial, Nature Communications, PCV, Cryptocurrency, Pharmaceutical industry, Neoplasm, Gritstone

EMERYVILLE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Molecular response, or reduction in ctDNA, is the primary efficacy endpoint for the Phase 2 portion of the GRANITE trial.
  • Gritstone delivered multiple presentations detailing advances in neoantigen prediction capabilities and cancer vaccine programs at the 2023 American Association for Cancer Research (AACR 2023, in April 2023).
  • Gritstone expects to initiate a randomized Phase 2 clinical trial within SLATE (“off-the-shelf” neoantigen vaccine program) in 2024.
  • Gritstone expects to share additional data from the CORAL-CEPI and CORAL-BOOST studies in Fall 2023.

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, August 9, 2023
BioNTech, CT, Nephrotoxicity, IV, Diabetes, Hospital, Mucor, Conference call, Clinical trial, Women's Hospital International and Fertility Centre, Infection, Brain, LNC, Research, Biomedical Research, European Congress of Ethnic Religions, Messenger, Lung, Acute myeloid leukemia, Development, MRI, Kidney, National Resilience Institute, ECCMID, MD, Patient, Standard of care, Azole, Microsoft Access, RNA interference, Fungal infection, FDA, Nationwide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Conference, NYSE, Food, Female, Pharmaceutical industry, Medical imaging, Antifungal

BEDMINSTER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) --  Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

Key Points: 
  • Matinas’ collaboration with National Resilience continues to focus on in vitro and in vivo delivery of mRNA and expects initial data later in 2023.
  • The Company reported no revenue for the second quarter of 2023 compared with $1.1 million of revenue for the second quarter of 2022, which was generated from the Company’s research collaborations with BioNTech SE.
  • Total costs and expenses for the second quarter of 2023 were $6.2 million compared with $7.0 million for the second quarter of 2022.
  • The net loss for the second quarter of 2023 was $6.1 million, or $0.03 per share, compared with a net loss for the second quarter of 2022 of $5.9 million, or $0.03 per share.

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Covid-19 hospital, Bemnifosbuvir, Patient, Risk, Arm, Income tax, Hospital, Week, New Drug Application, COVID-19, Atea, Viral, Fast Track, SOC, Virological failure, Infection, Disposable household and per capita income, Doctor of Philosophy, U.S. FDA, Congress, Development, ECCMID, Second generation, Standard of care, European, BID, Security (finance), Administration, SVR, Clutch (eggs), Adolescence, Research, FDA, Death, Regulation of tobacco by the U.S. Food and Drug Administration, Cirrhosis, HCV, Food, Safety, Pharmaceutical industry, Cryptocurrency

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • During the second quarter of 2023, we began dosing HCV patients, and we look forward to reporting initial results from our lead-in cohort of approximately 60 patients by year-end 2023,” continued Dr. Sommadossi.
  • Interest Income and Other, Net: Interest income and other, net was $7.3 million for the quarter ended June 30, 2023 compared to $1.1 million for the quarter ended June 30, 2022.
  • Income Tax Expense: Income tax expense remained relatively consistent at $0.3 million for the quarter ended June 30, 2023 compared to $0.1 million for the quarter ended June 30, 2022.

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

Retrieved on: 
Tuesday, June 20, 2023
MIC, XDR, Hemolysis, S. aureus, Methicillin-resistant Staphylococcus aureus, Daptomycin, MRSA, Cancer, ASM, Osteomyelitis, Acinetobacter, Yersinia pestis, Gram-negative bacteria, Staphylococcus aureus, Cons, Klebsiella pneumoniae, Pseudomonas aeruginosa, NPN, Knee, ECCMID, Animal, Lower respiratory tract infection, Patient, Ventilator-associated pneumonia, Meropenem, Fungal infection, Bacteria, Campaign, Amikacin, Food, Peptide, Staphylococcus, Vaccine, Yersinia, Burkholderia, MD, Klebsiella, Pseudomonas

“The data presented at ASM Microbe is quite powerful.

Key Points: 
  • “The data presented at ASM Microbe is quite powerful.
  • Both dose regimens of CF-370 in addition to amikacin significantly reduced bacteria counts compared to all other treatment groups (p≤0.0001).
  • The results of this study reproduce the efficacy seen in previously released data presented at ECCMID 2023 further demonstrating the bactericidal power of CF-370 against XDR strains of Gram-negative pathogens.
  • The results of this study reinforce previously released data demonstrating the power of both CF-296 and exebacase when delivered locally in the rabbit osteomyelitis model.

A.Menarini Diagnostics announces the release of the PRIME MDx platform

Retrieved on: 
Monday, May 22, 2023
Infection, Quality of life, Human Touch, Somatosensory system, ECCMID, COVID-19, AI, PCR, D, Medical device, Vaccine

is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR.

Key Points: 
  • is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR.
  • The Covid-19 pandemic has significantly reshaped the molecular diagnostics market, pushing it in the direction of seamless automation, ease-of-use, fast turn-around times and test reliability.
  • In spite of the significant advances in the domain, several testing applications still rely on laboratory-developed tests and labour-intensive techniques which make the implementation of large-scale automated diagnostics solutions inconvenient.
  • Today, it is present in 140 countries throughout the world, with more than 17,000 employees and 2022 turnover of € 4.155 billion.